China: A New Biopharma Model Emerging
Professor Richard Barker, founder of New Medicine Partners reflects on China’s very different approach to the biopharma industry. Napoleon once said: “China is a sleeping giant. Let her sleep, for…
Yunnan Baiyao Group Co., Ltd. manufactures and sells Chinese pharmaceutical products in China and internationally. The company provides Yunnan Baiyao series of products, including powders, capsules, plasters, woundplasts, and aerosols for activating blood circulation, dispersing blood stasis, reducing swelling, and relieving pain, as well as to treat traumatic injuries, rheumatic paralysis, pains in bones, muscle aches, and cold injuries. It also offers phytobiological medicines in the forms of oral liquids, tablets, powders, flower-leave granules, and capsules; and health products consisting of toothpastes, itching-relieving and smoothing essential skin cares, shower and foot bath effervescent tablets, shoe disinfectant and deodorize aerosols, and first aid kits. In addition, the company provides medicines, such as paracetamol, aminophenazone, caffeine, and chlorphenamine maleate tablets, as well as oxytetracycline tablets and norfloxacin capsules. Yunnan Baiyao Group Co., Ltd. is based in Kunming, China.
Professor Richard Barker, founder of New Medicine Partners reflects on China’s very different approach to the biopharma industry. Napoleon once said: “China is a sleeping giant. Let her sleep, for…
Chinese ecommerce behemoths Alibaba and JD.com are being used to buy and sell tens of thousands of prescription medicines, skirting regulations in what is a legal grey area. According to…
Andy A. Liu, CEO of CW Data Technologies, a joint venture between WuXi AppTec and China Electronics Data Corporation at the intersection of Big Data and healthcare, discusses emerging trends…
Simon Yam, managing director of Geodis Greater China, shares the importance of the Greater China region to Geodis globally, the region’s strong performance and growth, the strategic importance of the…
Gene Shigekawa, managing partner of MAZ World, shares their recent move to the Hong Kong Science and Technology Park (HKSTP) in 2017, the revolutionary ostrich-derived antibody they hope to further…
Louis Sze, CEO of Personal Surgical Modelling, an exciting Hong Kong start-up in the 3D printing medical technology field, shares the company’s achievements over the past few years, his insights…
K P Tsang, president of the Hong Kong Alliance for Rare Diseases (HKARD), shares the challenges faced by patients with rare diseases and their caregivers in Hong Kong, the areas…
Dr. Harley Seyedin, president of AmCham South China, talks up increasing connectivity in the region, competition and collaboration between the Greater Bay Area cities, and their potential for international life…
Rupert Mok, a veteran of the Hong Kong medtech industry, discusses regulatory alignment between Hong Kong and mainland China, opportunities for collaboration, the consumer ‘wearable’ space, and the state of…
This week, China has fast-tracked approval for 48 “much-needed medicines.” Regulators gave special consideration to new treatments for rare diseases as well as drugs that target serious, life-threatening illnesses, like cancer. Authorities…
One of China’s biggest vaccine manufacturers was found to have falsified rabies vaccine records causing nationwide parenting chaos. Executives from China’s second largest pharmaceutical company, ChangSheng biotechnology (Changsheng literally translates…
Dr. Qiu, could you please introduce your company, H-Guard, to our international readers? “It is clear that our efforts and investments over the past five years have paid off. Just…
See our Cookie Privacy Policy Here
